Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR⁺ ER⁺ HER^2- Metastatic Breast Cancer

Veru, Inc. announced that the US FDA has granted Fast Track designation to the Phase III registration program for the investigation of enobosarm for the treatment of androgen receptor positive, estrogen receptor positive, human epidermal growth factor receptor 2 negative (AR+ER+HER2-) metastatic breast cancer patients.